SetupAI
繁
SourceRecentcollected in 3h

Enveda Raises $311M for AI-Discovered Drugs

Read original on TechCrunch AI
#drug-discovery#biotech-funding#clinical-trials

A $2B-valued AI biotech is pushing nature-derived candidates into clinical testing.

30-Second TL;DR

What Changed

Enveda raised $311 million in new funding.

Why It Matters

The funding gives Enveda resources to move AI-identified natural-product candidates toward human testing. It also signals continued investor interest in AI-enabled drug discovery beyond purely computational demonstrations.

What To Do Next

Track Enveda’s clinical-trial registrations and published validation data before evaluating its platform for a biotech partnership.

Who should care:Founders & Product Leaders

Key Points

  • •Enveda raised $311 million in new funding.
  • •The financing valued the company at $2 billion.
  • •Clinical programs target skin conditions and preserving weight loss after GLP-1 treatment.
Key numbers$311 million$845 million85%$2 billion

Deep Insight

Background and context from public sources — not the original article. 8 sources cited.

Enhanced Key Takeaways

  • •The $311 million Series E financing was led by Catalio Capital Management, lifting Enveda's total capital raised since inception beyond $845 million.
  • •Enveda was founded in 2019 by CEO Viswa Colluru, Ph.D., an early employee at AI drug discovery pioneer Recursion Pharmaceuticals.
  • •The company's proprietary PRISM platform integrates tandem mass spectrometry with machine learning to decode, predict structures, and rank bioactive natural molecules.
  • •Lead asset ENV-294, an oral molecular glue targeting inflammatory pathways, demonstrated an 85% average reduction in eczema severity across a 42-day Phase 1b trial.
  • •Enveda is evaluating a third clinical asset, ENV-6946, designed as an oral multi-biologic in a pill for inflammatory bowel disease currently in Phase 1 trials.

Technical Deep Dive

  • Platform Architecture (PRISM): Couples high-throughput tandem mass spectrometry (MS/MS) with machine learning models to identify and structurally elucidate uncharacterized bioactive small molecules within natural plant and microbial extracts.
  • Discovery Approach: Explores metabolomic natural chemical space to identify pre-evolved bioactive molecules, contrasting with pure de novo in silico molecular design.
  • Molecular Glue Mechanics (ENV-294): Formulated as an orally bioavailable small-molecule molecular glue engineered to selectively modulate inflammatory signaling cascades for atopic dermatitis and asthma.
  • Targeted Delivery Design (ENV-6946): Designed as an oral multi-target small molecule that mimics the simultaneous pathway inhibition of multiple biologic therapies for inflammatory bowel disease.

Future ImplicationsAI analysis grounded in cited sources

Successful late-stage data will validate metabolomics-based AI over pure de novo generation.
If Enveda's clinical trials succeed, biopharma investment will increasingly shift capital toward mining natural chemical spaces with AI rather than relying strictly on unconstrained de novo computational design.
Oral post-GLP-1 therapies will establish a distinct chronic metabolic maintenance category.
Clinical advancement of ENV-308 could solve the weight-regain problem after GLP-1 discontinuation without requiring permanent use of injectable incretin mimetics.

Timeline

2019-01
Viswa Colluru founds Enveda Biosciences
2026-09
Enveda secures $311M Series E round at a $2B valuation
Read original article on TechCrunch AI

Weekly AI Recap

Read this week's curated digest of top AI events →

PostLinkedIn

AI-curated news aggregator. All content rights belong to original publishers.
Original source: TechCrunch AI ↗

This is a summary, not the original. Read the source, or get the weekly briefing.

The weekly digest

One email a week. Unsubscribe anytime.